The data will be presented at the upcoming 36th
'We're eager to share these latest results, which further support KarXT's differentiated safety and tolerability profile demonstrated in trials conducted to date and reinforce its potential to provide a broad range of clinically meaningful symptom improvements,' said
Details of the presentations are as follows
Poster Title: Categorical response rates, time course of response, and symptom domains of response with KarXT (xanomeline-trospium) in the EMERGENT-3 trial
Poster Number: P.1199
Date & Time:
Presenter:
Poster Title: Onset, duration, and severity of adverse events with KarXT (xanomeline-trospium) in the randomized, double-blind, placebo-controlled phase 3 EMERGENT-3 trial
Poster Number: P.1204
Date & Time:
Presenter:
Poster Title: The potential role of the M1/M4 muscarinic receptor agonist KarXT in the treatment of cognitive impairment in patients with schizophrenia
Poster Number: P.1232
Date & Time:
Presenter:
About KarXT
KarXT (xanomeline-trospium) is an investigational muscarinic antipsychotic in development for the treatment of schizophrenia and psychosis related to Alzheimer's disease. Through its novel mechanism of action, KarXT acts as a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, which is thought to mediate positive, negative, and cognitive symptoms of schizophrenia. Unlike existing treatments, KarXT does not directly block dopamine receptors, representing a potential new approach to treating schizophrenia.
About Schizophrenia
Schizophrenia is a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including 2.8 million people in the
About Karuna
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our goals to develop and commercialize our product candidates, and other statements identified by words such as 'could,' 'expects,' 'intends,' 'may,' 'plans,' 'potential,' 'should,' 'will,' 'would,' or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to obtain necessary funding, our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, risks relating to business interruptions, and other risks set forth under the heading 'Risk Factors' of our Annual Report on Form 10-K for the year ended
Contact:
Tel: (617) 352-9917
Email: asmith@karunatx.com
(C) 2023 Electronic News Publishing, source